Biolase Stock Working Capital
BIOLDelisted Stock | USD 0.05 0.02 27.46% |
BIOLASE fundamentals help investors to digest information that contributes to BIOLASE's financial success or failures. It also enables traders to predict the movement of BIOLASE Stock. The fundamental analysis module provides a way to measure BIOLASE's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BIOLASE stock.
BIOLASE |
BIOLASE Company Working Capital Analysis
BIOLASE's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current BIOLASE Working Capital | 5.2 M |
Most of BIOLASE's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BIOLASE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionIn accordance with the company's disclosures, BIOLASE has a Working Capital of 5.2 M. This is 98.78% lower than that of the Health Care Equipment & Supplies sector and 99.62% lower than that of the Health Care industry. The working capital for all United States stocks is 99.65% higher than that of the company.
BIOLASE Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BIOLASE's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BIOLASE could also be used in its relative valuation, which is a method of valuing BIOLASE by comparing valuation metrics of similar companies.BIOLASE is currently under evaluation in working capital category among its peers.
BIOLASE Fundamentals
Return On Equity | -5.05 | |||
Return On Asset | -0.27 | |||
Profit Margin | (0.44) % | |||
Operating Margin | (0.45) % | |||
Current Valuation | 13.65 M | |||
Shares Outstanding | 33.4 M | |||
Shares Owned By Insiders | 0.32 % | |||
Shares Owned By Institutions | 8.97 % | |||
Number Of Shares Shorted | 2.1 M | |||
Price To Earning | (7.23) X | |||
Price To Book | 0.77 X | |||
Price To Sales | 0.1 X | |||
Revenue | 49.16 M | |||
Gross Profit | 16.53 M | |||
EBITDA | (15.14 M) | |||
Net Income | (20.63 M) | |||
Cash And Equivalents | 9.96 M | |||
Cash Per Share | 1.39 X | |||
Total Debt | 17.91 M | |||
Debt To Equity | 1.07 % | |||
Current Ratio | 2.46 X | |||
Book Value Per Share | (0.06) X | |||
Cash Flow From Operations | (14.09 M) | |||
Short Ratio | 1.09 X | |||
Earnings Per Share | (11.97) X | |||
Price To Earnings To Growth | (0.22) X | |||
Target Price | 1.95 | |||
Number Of Employees | 157 | |||
Beta | 0.75 | |||
Market Capitalization | 4.31 M | |||
Total Asset | 35.1 M | |||
Retained Earnings | (316.8 M) | |||
Working Capital | 5.2 M | |||
Current Asset | 34.8 M | |||
Current Liabilities | 15.11 M | |||
Net Asset | 35.1 M |
About BIOLASE Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BIOLASE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BIOLASE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BIOLASE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in BIOLASE Stock
If you are still planning to invest in BIOLASE check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BIOLASE's history and understand the potential risks before investing.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |